Ocular delivery of triamcinolone acetonide phosphate and related compounds

• US 20080009471A1
• Filed: 07/10/2007
• Published: 01/10/2008
• Est. Priority Date: 10/27/2004
• Status: Abandoned Application

• Current Assignee: Aciont, Inc.
• Original Assignee: Aciont, Inc.
• Inventors: Higuchi, John, Kochambilli, Rajan, Li, S., Tuitupou, Anthony
• Application Number:
  US11/827,373
• Publication Number:
  US 20080009471A1
• Time in Patent Office: Days
• US Class Current: 514/171
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 41/00 Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61N 1/0412 Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
• CPC Class Codes: A61N 1/044 Shape of the electrode
• CPC Class Codes: A61N 1/303 Constructional details electrodes for external use A61N1/0428
• CPC Class Codes: A61N 1/327 for enhancing the absorption properties of tissue, e.g. by electroporation
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/38 : of the suprarenal hormones
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention provides systems and methods for ocularly delivering a triamcinolone acetonide agent to a subject. In one aspect, for example, a method is provided for treating or preventing an ocular condition in a subject for which triamcinolone acetonide is effective. Such a method may include ocularly administering a triamcinolone acetonide agent to the subject in order to treat or prevent the condition. Although any administration technique is contemplated, in some aspects a triamcinolone acetonide agent may be delivered to eye tissue via ocular iontophoresis.

Claims

1. A method for treating or preventing an ocular condition in a subject for which triamcinolone acetonide is effective, comprising:

administering a triamcinolone acetonide agent to an eye of the subject in order to treat or prevent the condition.

2. The method of claim 1, wherein the triamcinolone agent is a member selected from the group consisting of triamcinolone acetonide, triamcinolone acetonide phosphate, and combinations thereof.

3. The method of claim 2, wherein the triamcinolone agent is triamcinolone acetonide phosphate.

4. The method of claim 2, wherein the triamcinolone agent is triamcinolone acetonide.

5. The method of claim 4, wherein the triamcinolone acetonide is coadministered with a solubilizing agent.

6. The method of claim 1, wherein administering the triamcinolone acetonide agent further includes ocular iontophoretic administration.

7. The method of claim 1, wherein the condition is a member selected from the group consisting of macular edema, age related macular degeneration, anterior, intermediate, and posterior uveitis, HSV retinitis, diabetic retinopathy, bacterial, fungal, or viral endophthalmitis, eye cancers, glioblastomas, glaucoma, glaucomatous degradation of the optic nerve, and combinations thereof.

8. The method of claim 1, further comprising co-administering a vasoconstricting agent with the triamcinolone acetonide agent.

9. The method of claim 8, wherein the vasoconstricting agent is a member selected from the group consisting of naphazoline, tetrahydrozoline, phenylethylamine, epinephrine, norepinephrine, dopamine, dobutamine, colterol, ethylnorepinephrine, isoproterenol, isoetharine, metaproterenol, terbutaline, metearaminol, phenylephrine, tyramine, hydroxyamphetamine, ritrodrine, prenalterol, methoxyamine, oxymethazoline, albuterol, amphetamine, methamphetamine, benzphetamine, ephedrine, phenylpropanolamine, methentermine, phentermine, fenfluramine, propylhexedrine, diethylpropion, phenmetrazine, phendimetrazine, and combinations thereof.

10. The method of claim 9, wherein the vasoconstricting agent is oxymethazoline.

11. A system for treating or preventing a condition in a subject for which triamcinolone acetonide is effective, comprising:

an ocular device having a drug reservoir; and

a triamcinolone agent disposed within the drug reservoir.

12. The system of claim 11, wherein the triamcinolone agent is a member selected from the group consisting of triamcinolone acetonide, triamcinolone acetonide phosphate, and combinations thereof.

13. The system of claim 12, wherein the triamcinolone agent is triamcinolone acetonide phosphate.

14. The system of claim 11, wherein the ocular device is an iontophoretic ocular device.

15. The system of claim 14, further comprising a pernselective material functionally coupled to the drug reservoir.

16. The system of claim 11, wherein the ocular device further includes an enhancer reservoir configured to contain an enhancing agent.

17. The system of claim 16, wherein the enhancer reservoir contains a vasoconstricting agent.

18. The system of claim 17, wherein the vasoconstricting agent is a member selected from the group consisting of naphazoline, tetrahydrozoline, phenylethylamine, epinephrine, norepinephrine, dopamine, dobutamine, colterol, ethylnorepinephrine, isoproterenol, isoetharine, metaproterenol, terbutaline, metearaminol, phenylephrine, tyramine, hydroxyamphetamine, ritrodrine, prenalterol, methoxyamine, oxymethazoline, albuterol, amphetamine, methamphetamine, benzphetamine, ephedrine, phenylpropanolamine, methentermine, phentermine, fenfluramine, propylhexedrine, diethylpropion, phenmetrazine, phendimetrazine, and combinations thereof.

19. The system of claim 18, wherein the vasoconstricting agent is oxymethazoline.